Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer (stage IIIB, IIIC, or IV) that cannot be removed by surgery.
- Your cancer has the EGFR L858R mutation (a specific change in the EGFR gene).
- You have not had any previous cancer treatment, including chemotherapy, radiation, targeted therapy, or immunotherapy.
- You have at least one tumor that can be measured on scans.
- You are 18 years or older and able to care for yourself (ECOG score 0–3).
- Your blood counts, liver, and kidney function are within certain limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two oral targeted drugs—aumolertinib (which targets EGFR) and anlotinib (which blocks blood vessel growth to the tumor)—as a first treatment for advanced lung cancer that has both EGFR and TP53 mutations. It aims to see if the combination works better and is safe compared to standard care.
This trial tests a combination of two targeted drugs (almonertinib and anlotinib) as first treatment for advanced non-small cell lung cancer that has specific gene changes (EGFR and TP53 mutations). The goal is to see if the pair works better than standard care.
This trial tests a combination of aumolertinib (a targeted cancer drug) with chemotherapy in patients with advanced lung adenocarcinoma that has a specific genetic mutation called EGFR L858R. The goal is to see if this combination can slow or shrink the cancer better than existing treatments.
This trial tests a new combination of two targeted drugs (HS-20117 and aumolertinib) in people with advanced EGFR-mutant lung cancer who haven't had treatment yet. The goal is to see if the combination works better than current standard treatments.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
This trial tests whether taking aumolertinib (a pill that targets specific EGFR mutations) after lung cancer surgery helps prevent the cancer from coming back. It is for people with early-stage non-small cell lung cancer that has an EGFR mutation and has been completely removed.
Hear when a new Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.